CN106999591A - 一种抗pd‑1抗体制剂及其在医药上的应用 - Google Patents

一种抗pd‑1抗体制剂及其在医药上的应用 Download PDF

Info

Publication number
CN106999591A
CN106999591A CN201680003949.4A CN201680003949A CN106999591A CN 106999591 A CN106999591 A CN 106999591A CN 201680003949 A CN201680003949 A CN 201680003949A CN 106999591 A CN106999591 A CN 106999591A
Authority
CN
China
Prior art keywords
antibody
cancer
pharmaceutical preparation
polysorbate
trehalose dihydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201680003949.4A
Other languages
English (en)
Other versions
CN106999591B (zh
Inventor
李�杰
颜贞
王萍萍
方言
陶维康
张连山
孙飘扬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Rich Biological Medicine Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN106999591A publication Critical patent/CN106999591A/zh
Application granted granted Critical
Publication of CN106999591B publication Critical patent/CN106999591B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

一种稳定的抗PD‑1抗体药物制剂及其在医药上的应用。该抗PD‑1抗体药物制剂含有抗PD‑1抗体、缓冲剂,还可以含有至少一种稳定剂,任选的还可以含有表面活性剂。本发明的抗PD‑1抗体药物制剂可以有效地抑制抗体的聚集和脱酰胺作用,从而阻止抗体产品的降解,得到稳定的注射药物制剂。

Description

PCT国内申请,说明书已公开。

Claims (21)

  1. PCT国内申请,权利要求书已公开。
CN201680003949.4A 2015-09-28 2016-09-14 一种抗pd-1抗体制剂及其在医药上的应用 Active CN106999591B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510629020X 2015-09-28
CN201510629020 2015-09-28
PCT/CN2016/098982 WO2017054646A1 (zh) 2015-09-28 2016-09-14 一种抗pd-1抗体制剂及其在医药上的应用

Publications (2)

Publication Number Publication Date
CN106999591A true CN106999591A (zh) 2017-08-01
CN106999591B CN106999591B (zh) 2021-02-23

Family

ID=58422670

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680003949.4A Active CN106999591B (zh) 2015-09-28 2016-09-14 一种抗pd-1抗体制剂及其在医药上的应用

Country Status (13)

Country Link
US (2) US10786567B2 (zh)
EP (1) EP3357508A4 (zh)
JP (1) JP6921062B2 (zh)
KR (1) KR20180054791A (zh)
CN (1) CN106999591B (zh)
AU (1) AU2016329960A1 (zh)
BR (1) BR112018005349A2 (zh)
CA (1) CA2999079A1 (zh)
MX (1) MX2018003306A (zh)
RU (1) RU2731418C2 (zh)
TW (1) TWI721020B (zh)
UA (1) UA124259C2 (zh)
WO (1) WO2017054646A1 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111971062A (zh) * 2018-04-28 2020-11-20 齐鲁制药有限公司 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途
WO2021143767A1 (zh) * 2020-01-15 2021-07-22 信达生物制药(苏州)有限公司 结合pd-1和pd-l1的双特异性抗体的制剂及其用途
WO2021203769A1 (zh) * 2020-04-10 2021-10-14 江苏恒瑞医药股份有限公司 一种抗pd-1抗体在制备治疗肢端黑色素瘤的药物中的用途
CN114632150A (zh) * 2017-11-02 2022-06-17 正大天晴药业集团股份有限公司 一种抗pd-l1人源化单克隆抗体的药物组合物

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3081576T3 (pl) * 2013-12-12 2020-03-31 Shanghai Hengrui Pharmaceutical Co., Ltd. Przeciwciało anty pd-1, jego fragment wiążący antygen i ich zastosowanie medyczne
US10513558B2 (en) 2015-07-13 2019-12-24 Cytomx Therapeutics, Inc. Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof
US10323091B2 (en) 2015-09-01 2019-06-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
BR112018005349A2 (zh) 2015-09-28 2018-10-09 Suzhou Suncadia Biopharmaceuticals Co., Ltd. An anti-PD-1 antibody preparation and its application in medicine
EA201890790A1 (ru) 2015-09-29 2018-10-31 Селджин Корпорейшн Связывающие pd-1 белки и способы их применения
MA43186B1 (fr) 2015-11-03 2022-03-31 Janssen Biotech Inc Anticorps se liant spécifiquement à pd-1 et leurs utilisations
WO2018053401A1 (en) 2016-09-19 2018-03-22 Celgene Corporation Methods of treating vitiligo using pd-1 binding proteins
KR102257154B1 (ko) 2016-09-19 2021-05-28 셀진 코포레이션 Pd-1 결합 단백질을 사용하는 면역 질환의 치료 방법
AU2017373945A1 (en) 2016-12-07 2019-06-20 Agenus Inc. Antibodies and methods of use thereof
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US11845798B2 (en) 2017-05-02 2023-12-19 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
KR102623679B1 (ko) 2017-05-16 2024-01-11 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Pd-l1 항체 약학 조성물 및 이의 용도
BR112020001101A2 (pt) * 2017-07-25 2020-07-21 Jiangsu Hengrui Medicine Co., Ltd. composição farmacêutica do complexo de proteína il-15 e usos da mesma
CN111132696B (zh) * 2017-10-13 2023-05-16 江苏恒瑞医药股份有限公司 Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途
WO2019076277A1 (zh) * 2017-10-17 2019-04-25 江苏恒瑞医药股份有限公司 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
CN109793892B (zh) * 2017-11-16 2022-07-26 江苏恒瑞医药股份有限公司 一种抗pd-1抗体在制备治疗食管癌的药物中的用途
WO2019096194A1 (zh) * 2017-11-16 2019-05-23 江苏恒瑞医药股份有限公司 Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
CN109893654B (zh) * 2017-12-11 2021-07-27 江苏恒瑞医药股份有限公司 Vegfr抑制剂治疗肿瘤的方法
WO2019114785A1 (zh) * 2017-12-14 2019-06-20 江苏恒瑞医药股份有限公司 Pd-1抗体用于治疗肿瘤的用途
CA3093036A1 (en) * 2018-03-07 2019-09-12 Pfizer Inc. Anti-pd-1 antibody compositions
CN110272491B (zh) * 2018-03-13 2023-01-24 江苏恒瑞医药股份有限公司 一种抗pd-1抗体的纯化工艺
CN110448691A (zh) * 2018-05-07 2019-11-15 江苏恒瑞医药股份有限公司 抗pd-1抗体联合il-15蛋白复合物在制备治疗肿瘤的药物中的用途
JP2021534093A (ja) * 2018-08-20 2021-12-09 江蘇恒瑞医薬股▲ふん▼有限公司 腫瘍処置用医薬の製造におけるtim−3抗体の使用
CN112543646B (zh) * 2018-11-06 2023-11-14 江苏恒瑞医药股份有限公司 一种抗pd-1抗体和法米替尼联合在制备治疗肿瘤的药物中的用途
WO2020097139A1 (en) * 2018-11-07 2020-05-14 Merck Sharp & Dohme Corp. Co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
EP3876978A4 (en) * 2018-11-07 2022-09-28 Merck Sharp & Dohme Corp. STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (MP-1) ANTIBODIES AND THEIR METHODS OF USE
CN111346225A (zh) * 2018-12-21 2020-06-30 上海张江生物技术有限公司 含有蛋白质的药物制剂
CR20210435A (es) 2019-02-18 2021-09-20 Lilly Co Eli Formulación de anticuerpos terapéuticos
CN113874036A (zh) 2019-05-24 2021-12-31 辉瑞公司 使用cdk抑制剂的联合治疗
US20230355757A1 (en) 2019-12-20 2023-11-09 Formycon Ag Formulations of anti-pd1 antibodies
KR20210097882A (ko) * 2020-01-30 2021-08-10 삼성바이오에피스 주식회사 안정한 항-pd-1 항체 약제학적 제제
US20230295329A1 (en) * 2020-07-31 2023-09-21 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-pd-1 antibody pharmaceutical composition and use thereof
CN116472290A (zh) 2020-09-24 2023-07-21 默沙东有限责任公司 程序性死亡受体1(pd-1)抗体和透明质酸酶变体及其片段的稳定制剂及其使用方法
US20220168293A1 (en) 2020-12-02 2022-06-02 Pfizer Inc. Time to resolution of axitinib-related adverse events
CN115212209B (zh) * 2021-04-19 2023-11-28 中国科学院分子细胞科学卓越创新中心 一种具有免疫佐剂活性和促进免疫疗法的抗肿瘤药物
WO2022268887A1 (en) 2021-06-23 2022-12-29 Formycon Ag Formulations of anti-pd1 antibodies
WO2023037384A1 (en) * 2021-09-07 2023-03-16 Dr. Reddy's Laboratories Limited Formulations of immune check point inhibitors or like
TW202327595A (zh) 2021-10-05 2023-07-16 美商輝瑞大藥廠 用於治療癌症之氮雜內醯胺化合物的組合
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist
WO2024023843A1 (en) * 2022-07-26 2024-02-01 Dr. Reddy’S Laboratories Limited A pharmaceutical formulation of a therapeuticantibody and preparations thereof

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044908A2 (en) * 2004-10-20 2006-04-27 Genentech, Inc. Antibody formulation in histidine-acetate buffer
WO2007092772A2 (en) * 2006-02-03 2007-08-16 Medimmune, Inc. Protein formulations
WO2007110339A1 (en) * 2006-03-28 2007-10-04 F. Hoffmann-La Roche Ag Anti-igf-1r human monoclonal antibody formulation
WO2009007272A1 (en) * 2007-07-10 2009-01-15 F. Hoffmann-La Roche Ag Novel formulation
CN102892785A (zh) * 2010-03-11 2013-01-23 Ucb医药有限公司 生物学制品:人源化激动性抗-pd-1抗体
JP2013521768A (ja) * 2010-03-11 2013-06-13 ユセベ ファルマ ソシエテ アノニム Pd−1抗体
CN103429264A (zh) * 2011-03-31 2013-12-04 默沙东公司 针对人程序性死亡受体pd-1的抗体的稳定制剂和有关的治疗
WO2015001504A2 (en) * 2013-07-04 2015-01-08 Neotope Biosciences Limited Antibody formulations and methods
WO2015085847A1 (zh) * 2013-12-12 2015-06-18 上海恒瑞医药有限公司 Pd-1抗体、其抗原结合片段及其医药用途
WO2015119923A1 (en) * 2014-02-04 2015-08-13 Pfizer Inc. Combination of a pd-1 antagonist and a 4-abb agonist for treating cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1034292A (zh) * 1988-01-15 1989-07-26 翁文聘 异步整流发电机
WO1989011297A1 (en) * 1988-05-27 1989-11-30 Centocor, Inc. Freeze-dried formulation for antibody products
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
EP3530736A3 (en) * 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AU2010338305A1 (en) * 2009-12-29 2012-05-24 F. Hoffmann-La Roche Ag Antibody formulation
BR112018005349A2 (zh) 2015-09-28 2018-10-09 Suzhou Suncadia Biopharmaceuticals Co., Ltd. An anti-PD-1 antibody preparation and its application in medicine

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044908A2 (en) * 2004-10-20 2006-04-27 Genentech, Inc. Antibody formulation in histidine-acetate buffer
WO2007092772A2 (en) * 2006-02-03 2007-08-16 Medimmune, Inc. Protein formulations
WO2007110339A1 (en) * 2006-03-28 2007-10-04 F. Hoffmann-La Roche Ag Anti-igf-1r human monoclonal antibody formulation
WO2009007272A1 (en) * 2007-07-10 2009-01-15 F. Hoffmann-La Roche Ag Novel formulation
CN102892785A (zh) * 2010-03-11 2013-01-23 Ucb医药有限公司 生物学制品:人源化激动性抗-pd-1抗体
JP2013521768A (ja) * 2010-03-11 2013-06-13 ユセベ ファルマ ソシエテ アノニム Pd−1抗体
CN103429264A (zh) * 2011-03-31 2013-12-04 默沙东公司 针对人程序性死亡受体pd-1的抗体的稳定制剂和有关的治疗
WO2015001504A2 (en) * 2013-07-04 2015-01-08 Neotope Biosciences Limited Antibody formulations and methods
WO2015085847A1 (zh) * 2013-12-12 2015-06-18 上海恒瑞医药有限公司 Pd-1抗体、其抗原结合片段及其医药用途
WO2015119923A1 (en) * 2014-02-04 2015-08-13 Pfizer Inc. Combination of a pd-1 antagonist and a 4-abb agonist for treating cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WEI WANG ET AL.: ""Antibody Structure, Instability, and Formulation"", 《JOURNAL OF PHARMACEUTICAL SCIENCES》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114632150A (zh) * 2017-11-02 2022-06-17 正大天晴药业集团股份有限公司 一种抗pd-l1人源化单克隆抗体的药物组合物
CN114632150B (zh) * 2017-11-02 2023-12-19 正大天晴药业集团股份有限公司 一种抗pd-l1人源化单克隆抗体的药物组合物
CN111971062A (zh) * 2018-04-28 2020-11-20 齐鲁制药有限公司 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途
CN111971062B (zh) * 2018-04-28 2022-07-26 上海齐鲁制药研究中心有限公司 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途
WO2021143767A1 (zh) * 2020-01-15 2021-07-22 信达生物制药(苏州)有限公司 结合pd-1和pd-l1的双特异性抗体的制剂及其用途
WO2021203769A1 (zh) * 2020-04-10 2021-10-14 江苏恒瑞医药股份有限公司 一种抗pd-1抗体在制备治疗肢端黑色素瘤的药物中的用途

Also Published As

Publication number Publication date
WO2017054646A1 (zh) 2017-04-06
RU2018110333A3 (zh) 2019-12-30
AU2016329960A1 (en) 2018-04-26
JP6921062B2 (ja) 2021-08-18
KR20180054791A (ko) 2018-05-24
JP2018532730A (ja) 2018-11-08
EP3357508A1 (en) 2018-08-08
MX2018003306A (es) 2018-05-16
TW201711699A (zh) 2017-04-01
US10786567B2 (en) 2020-09-29
US20180339045A1 (en) 2018-11-29
UA124259C2 (uk) 2021-08-18
BR112018005349A2 (zh) 2018-10-09
TWI721020B (zh) 2021-03-11
EP3357508A4 (en) 2019-04-24
US20210000954A1 (en) 2021-01-07
RU2018110333A (ru) 2019-10-28
CA2999079A1 (en) 2017-04-06
CN106999591B (zh) 2021-02-23
RU2731418C2 (ru) 2020-09-02

Similar Documents

Publication Publication Date Title
CN106999591A (zh) 一种抗pd‑1抗体制剂及其在医药上的应用
US20240052036A1 (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
US20240058263A1 (en) Formulations of antibody
US20050175611A1 (en) Pharmaceutical preparation comprising an antibody against the EGF receptor
US20080112953A1 (en) Stable formulations
KR20090104017A (ko) A베타 항체 비경구 제제
JP2013515754A (ja) 新規な抗体製剤
CA3118144A1 (en) Co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
CN104105506A (zh) 抗-p-选择蛋白抗体制剂
AU2018280485A1 (en) Pharmaceutical composition comprising c-Met antibody-drug conjugate and use thereof
KR20220113355A (ko) 항-코넥신 항체 제제
AU2012200284B2 (en) Stable Antibody Formulations
CN117323430A (zh) 抗pcsk9抗体的制剂及其应用
CN116688115A (zh) 一种PD-L1/TGF-β双功能融合蛋白制剂及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20170825

Address after: 215126 No. 350 Feng Feng street, Suzhou Industrial Park, Jiangsu

Applicant after: Suzhou rich biological medicine Co., Ltd.

Applicant after: Hengrui Medicine Co., Ltd., Jiangsu Prov.

Applicant after: Hengrui Pharmaceutical Co., Ltd., Shanghai

Address before: 222047 Kunlun Road, Lianyungang economic and Technological Development Zone, Jiangsu, No. 7

Applicant before: Hengrui Medicine Co., Ltd., Jiangsu Prov.

Applicant before: Hengrui Pharmaceutical Co., Ltd., Shanghai

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1238156

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant